Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
29.27
+0.47 (1.63%)
Jul 28, 2026, 1:33 PM EDT - Market open

Genmab Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,9013,7203,1212,3902,0881,287
Revenue Growth
27.49%19.19%30.59%14.48%62.20%-22.45%
Cost of Revenue
26123814333--
Gross Profit
3,6403,4822,9782,3572,0881,287
Selling, General & Admin
666626549478385.16196.2
Research & Development
1,6871,6061,4141,107800.55639.39
Other Operating Expenses
23018543---
Total Operating Expenses
2,5832,4172,0061,5851,186835.59
Operating Income
1,0571,065972772902.02451.59
Interest Income
354408645299459254.93
Interest Expense
-377-269-291-254-361.41-107.35
Total Non-Operating Income (Expense)
-231393544597.59147.57
Pretax Income
9051,2041,326817999.61599.17
Provision for Income Taxes
168241193186214.89146.96
Net Income
7379631,133631784.72452.2
Net Income to Common
7379631,133631784.72452.2
Net Income Growth
89.46%-15.00%79.56%-19.59%73.53%-42.10%
Shares Outstanding (Basic)
552622642653654654
Shares Outstanding (Diluted)
559627647659660660
Shares Change
-13.51%-3.04%-1.88%-0.17%-0.06%0.24%
EPS (Basic)
1.331.551.770.971.200.69
EPS (Diluted)
1.321.541.750.961.190.68
EPS Growth
-25.16%-12.32%82.98%-19.50%75.00%-42.86%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
5841,1491,0991,018517.44302.18
Free Cash Flow Growth
-25.42%4.55%7.96%96.74%71.23%-69.95%
Free Cash Flow Per Share
1.041.831.701.540.780.46
Gross Margin
93.31%93.60%95.42%98.62%100.00%100.00%
Operating Margin
27.10%28.63%31.14%32.30%43.21%35.08%
Profit Margin
18.89%25.89%36.30%26.40%37.59%35.13%
FCF Margin
14.97%30.89%35.21%42.59%24.78%23.48%
EBITDA
1,1201,1361,032815954.13489.52
EBITDA Margin
28.71%30.54%33.07%34.10%45.70%38.03%
EBIT
1,0571,065972772902.02451.59
EBIT Margin
27.10%28.63%31.14%32.30%43.21%35.08%
Effective Tax Rate
18.56%20.02%14.56%22.77%21.50%24.53%
SEC Filings: 10-K · 10-Q